Home Merck Announces Third-Quarter 2013 Financial Results
 

Keywords :   


Merck Announces Third-Quarter 2013 Financial Results

2013-10-28 12:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. 2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS Breakthrough Therapy Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Mercks Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013.     $ in millions, except EPS amounts   ThirdQuarter2013   ThirdQuarter2012 Language: English Contact: MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
08.11African swine fever, labor and trade top of mind for Canadian pork industry
08.11Tech giants dominate U.S. streaming platform market
08.11Warner Bros. Discovery adds 7.2 million DTC subscribers in 3Q 2024
08.11Polyurea-Based Lining is Key to GRE Pipeline Rehab Project in UAE
08.11Parents paying over the odds for baby milk, watchdog warns
08.11Sports fans driving global growth in streaming services
08.11TiVo OS footprint approaching one million activated Smart TVs
08.11The Entertainer axes new shops after Budget tax rise
More »